1. Home
  2. ERO vs ARQT Comparison

ERO vs ARQT Comparison

Compare ERO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ero Copper Corp.

ERO

Ero Copper Corp.

N/A

Current Price

$37.58

Market Cap

2.8B

Sector

N/A

ML Signal

N/A

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

N/A

Current Price

$26.39

Market Cap

3.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ERO
ARQT
Founded
2016
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.2B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ERO
ARQT
Price
$37.58
$26.39
Analyst Decision
Buy
Buy
Analyst Count
18
7
Target Price
★ $40.73
$37.00
AVG Volume (30 Days)
1.2M
★ 2.4M
Earning Date
11-02-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 88.79
EPS
N/A
★ 0.03
Revenue
N/A
★ $376,072,000.00
Revenue This Year
$65.71
$42.98
Revenue Next Year
$9.87
$27.75
P/E Ratio
★ $22.61
$816.33
Revenue Growth
N/A
★ 91.34
52 Week Low
$19.09
$19.30
52 Week High
$40.83
$31.77

Technical Indicators

Market Signals
Indicator
ERO
ARQT
Relative Strength Index (RSI) 54.82 54.80
Support Level $23.83 $24.91
Resistance Level $40.00 $28.20
Average True Range (ATR) 1.46 1.33
MACD -0.04 -0.11
Stochastic Oscillator 60.39 59.45

Price Performance

Historical Comparison
ERO
ARQT

About ERO Ero Copper Corp.

Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: